Coronavirus information from UCLA and UCLA Health.

Magnify

The Next Generation Incubator

Pluto aims to build the next generation of “off-the-shelf” cellular immunotherapies.

Market:

We aim to change the way cancer is treated through unlimited in vitro production of tumor-optimized, functionally enhanced allogenic T cells. The projected market size for allogeneic cell therapy has been estimated as $~10.25B USD.

Technology:

Our platform system is the best-in-class for the generation of mature T cells from pluripotent stem cells (PSC). Only PSC can generate off-the-shelf products with the optimal complex gene edits required for targeting solid tumors.

Advantages:

    • - Best-in-class technology for generating mature T cells from a renewable source of induced pluripotent stem cells (iPSC)
    • Unlimited cell source
    • Unique potential for unlimited gene editing to engineer safer and more effective T cell therapies

Development Stage:

    • Pre-clinical

Select Publications:

Contact:

Email: info@plutoimmuno.com